Romark Laboratories Completes Enrollment In U.S. Phase II Study Of Nitazoxanide For Chronic...

medicalnewstoday.com     May 22, 2008            

Romark Laboratories, L.C., a privately-owned biopharmaceutical company, announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in U.S. patients with chronic hepatitis C genotype 1 who... [read full story]                

Full Coverage

Romark Completes Enrollment in Phase II Hepatitis Combination Therapy Study

redorbit.com     May 21, 2008          

Romark Laboratories has announced the completion of enrollment into its Phase II clinical trial to evaluate the safety and efficacy of nitazoxanide in combination with standard of care therapy in US patients with chronic hepatitis C genotype 1 who have previously failed to respond to the standard...                

comments